Accelerate Diagnostics, Inc. is a clinical-stage in vitro diagnostics company specializing in the rapid identification and antimicrobial susceptibility testing of infectious diseases. The company’s core offering is the Accelerate Pheno system, a fully automated platform designed to deliver both organism identification and phenotypic antimicrobial susceptibility results directly from positive blood cultures. By leveraging proprietary Morphokinetic Cellular Analysis (MCA) technology, Accelerate Diagnostics aims to significantly reduce the time required to guide appropriate antimicrobial therapy for patients with bloodstream infections.
Central to the company’s product portfolio is the PhenoTest BC Kit, which integrates with the Accelerate Pheno system to deliver actionable results in as little as seven hours, compared to traditional methods that can take up to 48 hours or more. In addition to its blood culture solutions, Accelerate Diagnostics is advancing its pipeline to include respiratory pathogen panels and other infectious disease targets, positioning the company to address a broad spectrum of hospital and reference laboratory needs.
Founded in 2008 and headquartered in Tucson, Arizona, Accelerate Diagnostics completed its initial public offering on the NASDAQ in 2019 under the ticker AXDX. Since inception, the company has secured regulatory clearances in the United States, European Union and other key markets, and has formed strategic collaborations with global distribution partners to expand its installed base. Accelerate Diagnostics has also invested in clinical research partnerships to validate the clinical impact and health economic benefits of its rapid diagnostic workflow.
Accelerate Diagnostics serves hospitals, academic medical centers and reference laboratories in North America, Europe and select Asia-Pacific markets. The company is guided by an experienced management team with deep expertise in medical diagnostics, regulatory affairs and commercial operations, alongside a board of directors that includes leaders in infectious disease research, laboratory medicine and healthcare innovation.
AI Generated. May Contain Errors.
